The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

Part of paid clinical trials in Huntingdon Valley, Pennsylvania.

Sponsor
Wills Eye
Study ID
NCT01710332
Phase
PHASE2
Status
Completed

Conditions

  • Central Serous Chorioretinopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Intravitreal Aflibercept Injection — DRUG
    GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total). GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total).

Study Details

A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.

Key Dates

Start date
Oct 31, 2012
Status verified
May 2017
Primary completion
Jun 30, 2013
Completion
Jun 30, 2013

Study Design

Enrollment
12 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intravitreal Aflibercept Injection (x4)
    2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times).
  • Experimental: Intravitreal Aflibercept Injection (x6)
    2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).

Primary Outcome Measure

Safety of Intravitreal Aflibercept Injection [ Time Frame: 6 months ]

Locations (2)

FacilityCityStateZIPSite coordinators
Mid Atlantic Retina- Huntingdon ValleyHuntingdon ValleyPennsylvania19006-
Mid Atlantic Retna- Wills Eye InstitutePhiladelphiaPennsylvania19107-

Find similar trials in Huntingdon Valley, PA

By research site
Mid Atlantic Retina- Huntingdon Valley· Huntingdon Valley, PAMid Atlantic Retna- Wills Eye Institute· Philadelphia, PA

Related Studies